Adam J. Townsend Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Adam J. Townsend is Chief Commercial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 92,453 shares of APLS, which is worth approximately $2.66 Million. The most recent transaction as insider was on Feb 12, 2024, when has been sold 1,148 shares (Common Stock) at a price of $67.77 per share, resulting in proceeds of $77,799. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 92.5K

0% 3M change

21.66% 12M change

Total Value Held $2.66 Million

Adam J. Townsend Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 12 2024	SELL Open market or private sale	$77,799 $67.77 p/Share	1,148 Reduced 1.23%	92,453 Common Stock
Jan 29 2024	SELL Open market or private sale	$58,110 $64.14 p/Share	906 Reduced 0.96%	93,601 Common Stock
Jan 22 2024	SELL Open market or private sale	$221,845 $65.0 p/Share	3,413 Reduced 3.49%	94,507 Common Stock
Jan 16 2024	SELL Open market or private sale	$149,320 $66.81 p/Share	2,235 Reduced 2.23%	97,920 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	23,748 Added 19.17%	100,155 Common Stock
Dec 01 2023	SELL Open market or private sale	$6,700,100 $60.91 p/Share	110,000 Reduced 59.01%	76,407 Common Stock
Dec 01 2023	BUY Exercise of conversion of derivative security	$1,659,900 $15.09 p/Share	110,000 Added 37.11%	186,407 Common Stock
May 03 2023	SELL Open market or private sale	$413,549 $82.71 p/Share	5,000 Reduced 6.17%	75,995 Common Stock
May 03 2023	BUY Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Added 5.81%	80,995 Common Stock
Apr 03 2023	SELL Open market or private sale	$370,250 $74.05 p/Share	5,000 Reduced 6.17%	75,995 Common Stock
Apr 03 2023	BUY Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Added 5.81%	80,995 Common Stock
Mar 03 2023	SELL Open market or private sale	$319,200 $63.84 p/Share	5,000 Reduced 6.17%	75,995 Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Added 5.81%	80,995 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$60,898 $58.5 p/Share	1,041 Reduced 1.35%	75,995 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	9,886 Added 11.37%	77,036 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$40,046 $51.21 p/Share	782 Reduced 1.15%	67,150 Common Stock
Feb 03 2023	SELL Open market or private sale	$279,250 $55.85 p/Share	5,000 Reduced 6.86%	67,932 Common Stock
Feb 03 2023	BUY Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Added 6.42%	72,932 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$29,076 $52.77 p/Share	551 Reduced 0.8%	67,932 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$99,519 $52.05 p/Share	1,912 Reduced 2.72%	68,483 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	27,488 Added 28.08%	70,395 Common Stock
Jan 03 2023	SELL Open market or private sale	$253,500 $50.7 p/Share	5,000 Reduced 10.44%	42,907 Common Stock
Jan 03 2023	BUY Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Added 9.45%	47,907 Common Stock
Dec 05 2022	SELL Exercise of conversion of derivative security	$75,450 $15.09 p/Share	5,000 Reduced 9.45%	47,907 Common Stock
Dec 05 2022	SELL Open market or private sale	$251,900 $50.38 p/Share	5,000 Reduced 10.44%	42,907 Common Stock

AJT

Adam J. Townsend

Chief Commercial Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account